Art. -Nr.: HY-N0145

Puerarin

32 Cited Publications

Kundenbewertung

Based on 32 publication(s) in Google Scholar

Puerarin is an isoflavone extracted from Pueraria root and is a 5-HT2C receptor antagonist. Puerarin inhibits the dorsal motor nucleus of the vagus (DMV)-vagus nerve pathway, which in turn leads to decreased fat absorption.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 99.06%
CAS. Nr.: 3681-99-0
Formel: C₂₁H₂₀O₉
Molecular Weight:416.38

Speicherung:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 1 year , -20°C, 6 months

Puerarin Chemical Structure

CAS. Nr.: 3681-99-0

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- IC₅₀ & Target
- In Vitro
- In Vivo
- Clinical Trial
Chemical Information
Publications (32)
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Protokoll
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

IC₅₀ & Target

5-HT_2C Receptor

Alle 5-HT Receptor Isoform-spezifische Produkte anzeigen :

In Vitro

Puerarin inhibits the expression of LPS-induced iNOS, COX-2 and CRP proteins and also suppresses their mRNAs from RT-PCR experiments in RAW264.7 cells. The inhibition of iNOS, COX-2 and CRP expression is due to a dose-dependent inhibition of phosphorylation and degradation of I-κB, which resulted in the reduction of p65NF-κB nuclear translocation. The effect of puerarin-mediated inhibition of LPS-induced iNOS, COX-2 and CRP expression is attributed to suppressed NF-κB activation at the transcriptional level^[1].
Puerarin is a novel open-channel blocker of IK1, which may underlie the antiarrhythmic action of puerarin. Puerarin competes with barium, an open-channel blocker of IK1, to inhibit IK1 currents^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Both genistein and puerarin effectively alleviate hepatic damage induced by chronic alcohol administration through potential antioxidant, anti-inflammatory, or anti apoptotic mechanisms. However, genistein is more effective than puerarin in decreasing levels of malondialdehyde (1.05±0.0947 vs. 1.28±0.213 nmol/mg pro, p< 0.05), tumor necrosis factor α (3.12±0.498 vs. 3.82±0.277 pg/mg pro, p < 0.05), interleukin-6 (1.46±0.223 vs. 1.88±0.309 pg/mg pro, p < 0.05), whereas puerarin is more effective than genistein in ameliorating serum activities or levels of alanine transaminase (35.8±3.95 vs. 42.6±6.56 U/L, p < 0.05) and low-density lipoprotein cholesterol (1.12±0.160 vs. 1.55±0.150 mmol/L, p < 0.05) ^[3].
Early-stage renal damages can be significantly improved by puerarin, possibly via its suppression of ICAM-1 and TNF-α expression in diabetic rat kidneys^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

Chemical Information

CAS. Nr. 3681-99-0
Appearance Solid
Molecular Weight 416.38
Formel C₂₁H₂₀O₉
Color White to off-white
SMILES

O=C1C(C2=CC=C(O)C=C2)=COC3=C([C@H]4[C@@H]([C@H]([C@@H]([C@@H](CO)O4)O)O)O)C(O)=CC=C13
Structure Classification
- Flavonoids
- Isoflavones
- Phenols
- Polyphenols
Initial Source
Versand

Room temperature in continental US; may vary elsewhere.

Speicherung

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	1 year
	-20°C	6 months

Publications (32)

All IFFlow CytometryBio/Physico-chemical AssayWB

Sort by:

Journal Impact Factor

Acta Pharm Sin B

Chrysin serves as a novel inhibitor of DGK α/FAK interaction to suppress the malignancy of esophageal squamous cell carcinoma (ESCC). [Abstract]

2021 Jan;11(1):143-155. PMID: 33532186
Adv Sci (Weinh)

Puerarin Targets MIC19 to Suppress Mitochondrial Metabolism of Tumor-Infiltrating Tregs and Enhance Anti-tumor Immunity. [Abstract]

2025 Nov 18:e12793. PMID: 41250935

Puerarin purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2025 Nov 18:e12793. [Abstract]

Immunofluorescence staining of CD4⁺FOXP3⁺ Treg infiltration in HCC model mice treated with PBS or Puerarin (PUE: 2.0 mg/kg, daily).

Puerarin purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2025 Nov 18:e12793. [Abstract]

Flow cytometry analysis of Ti‐Tregs and CD4⁺/CD8⁺ T cell ratios in HCC model mice treated with PBS or Puerarin (PUE: 2.0 mg/kg, daily).

Puerarin purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2025 Nov 18:e12793. [Abstract]

FOXP3 expression in naïve CD4⁺ T cells isolated from mice spleens and co‐cultured with Hepa53.4 cells following stimulation with anti‐CD3/CD28 magnetic beads and interleukin (IL‐2), in the presence of increasing concentrations of Puerarin (PUE: 0, 20, 40, 60 µM) for 3 days.

Puerarin purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2025 Nov 18:e12793. [Abstract]

Puerarin (0-60 μM; 3 days). The level of transforming growth factor (TGF)-β in mouse Ti-Treg cells in the culture supernatant was detected by enzyme-linked immunosorbent assay (ELISA).

Puerarin purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2025 Nov 18:e12793. [Abstract]

Western blot analysis of mitochondrial respiratory chain complex subunits (Complex I–V) in mice Ti‐Tregs treated with PBS or Puerarin (PUE: 2.0 mg/kg, daily).
Chem Eng J

2026 Feb 4.
Chem Eng J

2026 Jan 24;530:173330.
Phytomedicine

Puerarin mitigates tumor necrosis factor-nuclear factor-κB axis-driven macrophage inflammation and atherogenesis: Integrative network pharmacology and experimental validation. [Abstract]

2026 May:154:158025. PMID: 41795298
Phytomedicine

Fangchinoline suppresses nasopharyngeal carcinoma progression by inhibiting SQLE to regulate the PI3K/AKT pathway dysregulation. [Abstract]

2025 May:140:156484. PMID: 40090046
Phytomedicine

Puerarin mitigates cognitive decline and white matter injury via CD36-Mediated microglial phagocytosis in chronic cerebral hypoperfusion. [Abstract]

2025 Mar:138:156396. PMID: 39827816
Food Chem

Effects of sun drying combined with baking processes on the flavor quality of Chongqing Tuocha raw tea. [Abstract]

2025 Dec 30:497:146992. PMID: 41285060
Food Chem

Flavonoid-mediated metabolic underpinning quality variation in red bud-sport pear mutants. [Abstract]

2025 Oct 15:489:144992. PMID: 40466530
Int J Nanomedicine

Lignin/Puerarin Nanoparticle-Incorporated Hydrogel Improves Angiogenesis through Puerarin-Induced Autophagy Activation. [Abstract]

2023 Sep 8:18:5095-5117. PMID: 37705868
Phytother Res

Puerarin attenuates hepatic steatosis via G-protein-coupled estrogen receptor-mediated calcium and SIRT1 signaling pathways. [Abstract]

2022 Sep;36(9):3601-3618. PMID: 35871535
Free Radic Biol Med

Puerarin mitigates cerebral ischemia/reperfusion (CIR)-induced ferroptosis by suppressing Ser15 phosphorylation-mediated p53 activation. [Abstract]

2025 Jun 10:237:383-396. PMID: 40505745
Free Radic Biol Med

Sequestered SQSTM1/p62 crosstalk with Keap1/NRF2 axis in hPDLCs promotes oxidative stress injury induced by periodontitis. [Abstract]

2022 Sep:190:62-74. PMID: 35940517
J Agric Food Res

2025 Mar 25.
Lipids Health Dis

Puerarin ameliorates metabolic dysfunction-associated fatty liver disease by inhibiting ferroptosis and inflammation. [Abstract]

2023 Nov 24;22(1):202. PMID: 38001459
J Ethnopharmacol

Serum metabolomics and 16S rRNA amplicon sequencing reveal the role of puerarin in alleviating bone loss aggravated by antidiabetic agent pioglitazone in type 2 diabetic mice. [Abstract]

2025 Jan 31:340:119128. PMID: 39617084
J Ethnopharmacol

Exploring the pathogenesis of type 2 diabetes mellitus intestinal damp-heat syndrome and the therapeutic effect of Gegen Qinlian Decoction from the perspective of exosomal miRNA. [Abstract]

2022 Mar 1:285:114786. PMID: 34763043
Eur J Pharmacol

Puerarin enhances TFEB-mediated autophagy and attenuates ROS-induced pyroptosis after ischemic injury of random-pattern skin flaps. [Abstract]

2024 Jul 5:974:176621. PMID: 38679118
Mol Med Rep

Puerarin alters the function of monocytes/macrophages and exhibits chondroprotection in mice. [Abstract]

2019 Apr;19(4):2876-2882. PMID: 30720093
J Cell Mol Med

Puerarin Protects Myocardium From Ischaemia/Reperfusion Injury by Inhibiting Ferroptosis Through Downregulation of VDAC1. [Abstract]

2024 Dec;28(24):e70313. PMID: 39730981
BMC Complement Med Ther

Effects and mechanisms of puerarin against neuroblastoma: insights from bioinformatics and in vitro experiments. [Abstract]

2024 Jul 9;24(1):257. PMID: 38982456
Naunyn Schmiedebergs Arch Pharmacol

Study on the mechanism of puerarin against osteoarthritis from ferroptosis based on network pharmacology and bioinformatics. [Abstract]

2024 Feb;397(2):959-968. PMID: 37548663
Toxicol Appl Pharmacol

Puerarin inhibits SiO2-induced pulmonary epithelial-mesenchymal transition via suppressing NF-κB activation: Insights from network pharmacology and experiment validation. [Abstract]

2026 May 13:117871. PMID: 42134512
J Cancer Res Clin Oncol

Comprehensive analysis based on spatial domains identifies CD44 as a potential target of puerarin. [Abstract]

2025 Dec 17;152(1):12. PMID: 41405724
Chem Biol Drug Des

Puerarin Decreases the Expression of FUS-Dependent MAPK4 to Inhibit the Development of Triple-Negative Breast Cancer. [Abstract]

2024 Sep;104(3):e14617. PMID: 39223105
Mol Biotechnol

Network Pharmacology and Experimental Validation Unravel How Puerarin Improves Chronic Postoperative Pain. [Abstract]

2025 Nov 7. PMID: 41204032
Kaohsiung J Med Sci

Combined Effects of Puerarin and Adipose-Derived Stem Cells on Alveolar Bone Preservation and Inflammation Control in Periodontitis Through p38MAPK Modulation. [Abstract]

2026 Feb 3:e70182. PMID: 41631577
Chem Biodivers

Secondary Metabolites from the Endophytic Fungus Letendraea helminthicola A820 with Anti-inflammatory Activity. [Abstract]

2025 Feb;22(2):e202402114. PMID: 39340168
Biochem Biophys Res Commun

Puerarin reduces cell damage from cerebral ischemia-reperfusion by inhibiting ferroptosis. [Abstract]

2024 Jan 22:693:149324. PMID: 38101001
Dent Mater J

Titanium surfaces loaded with puerarin and exosomes derived from adipose stem cells promote the proliferation and differentiation of pre-osteoblasts. [Abstract]

2024 Dec 10;43(6):780-788. PMID: 39358307
SSRN

2026 May 5.
University of Paris

2022 Sep 19.

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : 50 mg/mL (120.08 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.4017 mL

12.0083 mL

24.0165 mL

5 mM

0.4803 mL

2.4017 mL

4.8033 mL

10 mM

0.2402 mL

1.2008 mL

2.4017 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 3 mg/mL (7.20 mM); Clear solution

This protocol yields a clear solution of ≥ 3 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (30.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 3 mg/mL (7.20 mM); Clear solution

This protocol yields a clear solution of ≥ 3 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (30.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: 3 mg/mL (7.20 mM); Suspended solution; Need ultrasonic

This protocol yields a suspended solution of 3 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (30.0 mg/mL) to 900 μL Corn oil, and mix evenly.

Working Solution

For the following dissolution methods, please prepare the working solution directly:

It is recommended to prepare fresh solutions and use them promptly within a short period of time.

The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 50% PEG300 50% Saline

Solubility: 25 mg/mL (60.04 mM); Clear solution; Need ultrasonic

Protocol 2

Add each solvent one by one: 20% SBE-β-CD in Saline

Solubility: 20 mg/mL (48.03 mM); Clear solution; Need ultrasonic

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Protokoll

Cell Assay^[1]

RAW264.7 cells are maintained at subconfluence in 95% air and 5% CO₂ humidified atmosphere maintained at 37°C. The medium used for routine subculture is Dulbecco’s Modified Eagle’s Medium supplemented with 10% fetal bovine serum, penicillin (100 units/mL) and streptomycin (100 μg/ mL). An MTT assay is used to measure the viability of the cells after treatment with puerarin. After the supernatants are removed for nitrite determination, cells are incubated at 37°C with MTT (0.05 mg/mL) for 4 h, and the optical density is measured at 540 nm. The concentrations of puerarin are10, 20, 40 and 100 μM^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Administration^[3]^[4]

Rats: A cohort of healthy male SD rats (7 weeks old) are randomLy divided into a control group, a model group, and a puerarin treatment group with high (H), moderate (M), and low (L) dosage. Puerarin is re-suspended in 0.9% saline and is given by intra-gastric intubation at various concentrations (0.25 mg/(kg×d) for L group, 0.5 mg/(kg×d) for M group, and 1.0 mg/(kg×d) for H group) each day for 8 consecutive days. An equal volume of saline is administered to control and model rats during the same time period^[4].

Mice: Forty male ICR mice (weight: 20-22 g) are acclimatized with a daily 12 h light:12 h dark cycle at 22±2 °C room temperature and 55%±5% relative humidity. After 1 week of adaption, the mice are randomLy divided into four groups with ten mice per group. Genistein and puerarin are applied to the mice in sodium carboxymethyl cellulose solution with an equimolar concentration of 0.1 M (gastric volume: 3 mL kg^-1 body weight)^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (286 KB)
SDS (396 KB)
- English - EN (396 KB)
- Français - FR (396 KB)
- Deutsch - DE (396 KB)
- Norwegian - NO (396 KB)
- Español - ES (396 KB)
- Swedish - SV (396 KB)
- Italian - IT (396 KB)
- Korean - KR (396 KB)
- Portuguese - PT (396 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Hu W, et al. Puerarin inhibits iNOS, COX-2 and CRP expression via suppression of NF-κB activation in LPS-induced RAW264.7 macrophage cells. Pharmacol Rep. 2011;63(3):781-9. [Content Brief]

[2]. Zhang H, et al. Puerarin: a novel antagonist to inward rectifier potassium channel (IK1). Mol Cell Biochem. 2011 Jun;352(1-2):117-23. [Content Brief]

[3]. Zhao L,et al. Protective Effects of Genistein and Puerarin against Chronic Alcohol-Induced Liver Injury in Mice via Antioxidant, Anti-inflammatory, and Anti-apoptotic Mechanisms. J Agric Food Chem. 2016 Sep 28;64(38):7291-7. [Content Brief]

[4]. Pan X, et al. Effect of Puerarin on Expression of ICAM-1 and TNF-α in Kidneys of Diabetic Rats. Med Sci Monit. 2015 Jul 23;21:2134-40. [Content Brief]

[5]. Lyu, et al. "A brain-to-gut signal controls intestinal fat absorption." Nature (2024): 1-8. [Content Brief]

[6]. Liu S , et al. The in silico and in vivo evaluation of puerarin against Alzheimer's disease. Food Funct. 2019 Feb 20;10(2):799-813. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.4017 mL	12.0083 mL	24.0165 mL	60.0413 mL
	5 mM	0.4803 mL	2.4017 mL	4.8033 mL	12.0083 mL
	10 mM	0.2402 mL	1.2008 mL	2.4017 mL	6.0041 mL
	15 mM	0.1601 mL	0.8006 mL	1.6011 mL	4.0028 mL
	20 mM	0.1201 mL	0.6004 mL	1.2008 mL	3.0021 mL
	25 mM	0.0961 mL	0.4803 mL	0.9607 mL	2.4017 mL
	30 mM	0.0801 mL	0.4003 mL	0.8006 mL	2.0014 mL
	40 mM	0.0600 mL	0.3002 mL	0.6004 mL	1.5010 mL
	50 mM	0.0480 mL	0.2402 mL	0.4803 mL	1.2008 mL
	60 mM	0.0400 mL	0.2001 mL	0.4003 mL	1.0007 mL
	80 mM	0.0300 mL	0.1501 mL	0.3002 mL	0.7505 mL
	100 mM	0.0240 mL	0.1201 mL	0.2402 mL	0.6004 mL

Keywords

Puerarin

32 Cited Publications

100 mg Angebot einholen

Subscribe to the

MedChemExpress

Newsletter

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

Puerarin

Anti-Infection Compound Library

GPCR/G Protein Compound Library

Immunology/Inflammation Compound Library

Neuronal Signaling Compound Library

Natural Product Library

FDA-Approved Drug Library

Anti-Cancer Compound Library

CNS-Penetrant Compound Library

Drug Repurposing Compound Library

Anti-diabetic Compound Library

Glycoside Compound Library

Anti-Cardiovascular Disease Compound Library

Anti-COVID-19 Compound Library

NMPA-Approved Drug Library

Medicine Food Homology Compound Library

Phenols Library

Orally Active Compound Library

Neurotransmitter Receptor Compound Library

Traditional Chinese Medicine Active Compound Library

FDA Approved & Pharmacopeial Drug Library

Flavonoids Library

Anti-Alzheimer's Disease Compound Library

Anti-Parkinson's Disease Compound Library

Neurodegenerative Disease-related Compound Library

Rare Diseases Drug Library

Anti-Cancer Natural Product Library

Anti-inflammatory Traditional Chinese Medicine Active Compound Library

Plant-Sourced Natural Product Library

5-HT Receptor Compound Library

FDA-Approved Anticancer Drug Library

Human Metabolite Library

Coagulation and Anti-coagulation Compound Library

Off-patent Drug Library

Membrane Protein-targeted Compound Library

Membrane Receptor-targeted Compound Library

Highly Selective Inhibitors Library

FDA-Approved Traditional Chinese Medicine Active Compound Library

Multi-Target Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Natural Product Library Plus

Drug Repurposing Compound Library Plus

FDA-Approved Drug Library Plus

FDA-Approved Drug Library Mini

Natural Product and Natural Product-Like Compound Library

Bioactive Compound Library

Miao Ethnicity Medicine Compound Library

PBCRBS Traditional Chinese Medicine Compound Library

Heat-Clearing and Detoxification Traditional Chinese Medicine Compound Library

High-Throughput Bioactive Compound Library

High-Throughput Natural Product Library

Ancient Chinese Classical Formulas Traditional Chinese Medicine Active Compound Library

Mass Spectrometry Human Metabolite Library

Antitussive and Antiasthmatic Traditional Chinese Medicine Active Compound Library

Diarrhea-Related Traditional Chinese Medicine Active Compound Library

Mongolian Medicine Compound Library

Natural Product Diversity Scaffold Library

RNA Binding Bioactive Compound Library

Lactylation Compound Library

Mass Spectrometry Natural Product Library

Publications Citing Use of MedChemExpress (MCE) Puerarin

Alle 5-HT Receptor Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Publications (32)

Lösungsmittel & Löslichkeit

Protokoll

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

Puerarin Related Classifications

HY-N0145 Related Classifications